5,245 Shares in IDEXX Laboratories, Inc. $IDXX Bought by Barbara Oil Co.

Key Points

• Barbara Oil Co. acquired 5,245 IDEXX Laboratories shares during the second quarter, valued at approximately $2.8 million. Institutional investors collectively own 87.84% of the company.
• Analyst sentiment remains positive but mixed, with six Buy ratings and four Hold ratings. IDEXX has an average “Moderate Buy” rating and an average price target of $747.
• IDEXX reported quarterly earnings of $4.27 per share, beating estimates of $3.94, while revenue rose 9.7% year over year to $1.22 billion. Shares opened at $556.93, near the lower end of their 12-month range.

Barbara Oil Co. acquired a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) during the second quarter, according to the company in its most recent filing with the SEC. The fund acquired 5,245 shares of the company's stock, valued at approximately $2,805,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in IDXX. Elyxium Wealth LLC purchased a new position in IDEXX Laboratories in the fourth quarter valued at about $3,666,459,000. State Street Corp raised its position in shares of IDEXX Laboratories by 4.0% in the 4th quarter. State Street Corp now owns 3,656,626 shares of the company's stock valued at $2,473,817,000 after purchasing an additional 138,956 shares in the last quarter. J. Stern & Co. LLP raised its position in shares of IDEXX Laboratories by 23,694.7% in the 4th quarter. J. Stern & Co. LLP now owns 2,653,351 shares of the company's stock valued at $1,795,072,000 after purchasing an additional 2,642,200 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of IDEXX Laboratories by 3.5% during the 4th quarter. Geode Capital Management LLC now owns 2,583,939 shares of the company's stock valued at $1,749,380,000 after buying an additional 86,263 shares during the last quarter. Finally, Invesco Ltd. grew its position in shares of IDEXX Laboratories by 13.8% during the fourth quarter. Invesco Ltd. now owns 1,502,218 shares of the company's stock worth $1,016,296,000 after buying an additional 181,955 shares in the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

IDXX has been the topic of several recent analyst reports. Barclays cut their price target on shares of IDEXX Laboratories from $800.00 to $710.00 and set an "overweight" rating on the stock in a report on Tuesday, August 11th. Weiss Ratings upgraded shares of IDEXX Laboratories from a "hold (c)" rating to a "hold (c+)" rating in a research note on Wednesday, July 29th. UBS Group increased their price target on shares of IDEXX Laboratories from $620.00 to $670.00 and gave the stock a "neutral" rating in a research report on Wednesday, August 5th. Citigroup lifted their price target on IDEXX Laboratories from $650.00 to $670.00 and gave the stock a "neutral" rating in a research note on Wednesday, August 5th. Finally, Wall Street Zen lowered IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Sunday, July 12th. Six research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $747.00.

IDEXX Laboratories Stock Performance

IDEXX Laboratories stock opened at $556.93 on Monday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.17 and a quick ratio of 0.87. IDEXX Laboratories, Inc. has a 12 month low of $518.55 and a 12 month high of $769.98. The company has a fifty day moving average price of $560.01 and a two-hundred day moving average price of $576.43. The company has a market cap of $43.87 billion, a PE ratio of 39.17, a P/E/G ratio of 2.97 and a beta of 1.54.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported $4.27 earnings per share for the quarter, topping analysts' consensus estimates of $3.94 by $0.33. IDEXX Laboratories had a net margin of 25.03% and a return on equity of 71.96%. The company had revenue of $1.22 billion for the quarter, compared to analysts' expectations of $1.20 billion. During the same period in the prior year, the company earned $3.50 earnings per share. The firm's revenue was up 9.7% compared to the same quarter last year. IDEXX Laboratories has set its FY 2026 guidance at 14.690-14.940 EPS. Research analysts expect that IDEXX Laboratories, Inc. will post 14.81 earnings per share for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc NASDAQ: IDXX is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX's product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source